Neuropeptides and brain development. Current perils and future potential.
D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000818:Animals; D001692:Biological Transport; D001921:Brain / Q000187:drug effects / Q000196:embryology / Q000254:growth & development* / Q000378:metabolism; D004723:Endorphins / Q000494:pharmacology; D005260:Female; D006801:Humans; D009074:Melanocyte-Stimulating Hormones / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009474:Neurons / Q000378:metabolism; D010121:Oxytocin / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology* / Q000502:physiology; D010906:Pituitary Hormone-Releasing Hormones / Q000502:physiology; D010907:Pituitary Hormones / Q000502:physiology; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D051381:Rats; D012737:Sex Factors; D014667:Vasopressins / Q000494:pharmacology; D001615:beta-Endorphin
D004723:Endorphins; D010455:Peptides; D010906:Pituitary Hormone-Releasing Hormones; D010907:Pituitary Hormones; D014667:Vasopressins; D009270:Naloxone; D010121:Oxytocin; D001615:beta-Endorphin; D000324:Adrenocorticotropic Hormone; D009074:Melanocyte-Stimulating Hormones